TCS, Infosys, Accenture workforce to receive free Covid-19 vaccination

By Nikita Chaurasia  Date: 2021-03-05

TCS, Infosys, Accenture workforce to receive free Covid-19 vaccination

Information technology giants Infosys, Accenture India, and Tata Consultancy Services will reportedly cover Covid-19 vaccination costs for their employees and their family, who are eligible and opt to receive the jab.

This news comes along the heels of a tweet from businessman Suhel Seth requesting India’s top 1000 companies to cover all expenses of Covid-19 vaccine for their employees, to which, Anand Mahindra, Chairman of Mahindra group, responded by saying that the company had made this offer quite a while back and is just awaiting permission.

A TCS spokesperson said that ever since the onset of the pandemic, the organization has supported complete treatment and care of all associates and their families across the globe with its well-being programs. The person further expressed that the employee wellbeing program, TCS Cares, offers emotional support for holistic care, and will remain committed to the cause throughout the vaccination phase.

Pravin Rao, Chief Operating Officer of Infosys, on the matter, stated that Infosys is eyeing to partner up with healthcare providers to vaccinate employees and their families eligible under the government guidelines, approved procedures, and timelines.

Accenture India also confirmed that the organization will cover the cost for its employee and dependents with Chairperson and Senior Managing Director, Rekha M Menon, expressing said that nothing is more important than the health and well-being of our people as we continue to navigate the pandemic.

For the record, India initiated the third phase of Covid-19 vaccinations starting March 1 for all eligible citizens aged above 60 years and for adults aged 45-59 years with specific co-morbidities.

Prime Minister Narendra Modi, on Monday, was the first to get inoculated with Covaxin, the vaccine developed at Delhi’s All India Institute of Medical Sciences by India’s Bharat Biotech.

Sources Credits –

https://www.business-standard.com/article/companies/accenture-to-bear-covid-19-vaccine-cost-for-eligible-employees-dependents-121030300900_1.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

By Nikita Chaurasia

Leading Testing as a Service (TaaS) provider, 1health, recently announced that it has partnered with SkyWest Airlines, a SkyWest Inc. subsidiary, to provide two types of COVID-19 tests to the airline’s personnel. Mehdi Maghsoodnia, CEO at 1hea...

FBI to remove backdoors from hacked Microsoft Exchange email servers

FBI to remove backdoors from hacked Microsoft Exchange email servers

By Nikita Chaurasia

Following the recent cyber-attack in the US, a court in Houston has reportedly authorized a new FBI operation to copy and eliminate backdoors from large number of Microsoft Exchange email servers across the country. During this hacking event, the hac...

France might ban short domestic flights to reduce its carbon footprint

France might ban short domestic flights to reduce its carbon footprint

By Nikita Chaurasia

French lawmakers recently came to a unanimous decision to ban domestic flights for distances that can be covered by train in over two-and-a-half- hours. The country aims to impose these restrictions in an effort to reduce carbon emissions, even as th...

Kavak secures USD 485 million in funding, eyes Latin America expansion

Kavak secures USD 485 million in funding, eyes Latin America expansion

By Nikita Chaurasia

Kavak, a Mexico-based used-car platform, has reportedly reached a valuation of USD 4 billion after securing USD 485 million during a new funding round. This makes it the fastest-growing as well as the most valued company in Latin America. The latest...

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical t...